High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series

Hereditary Cancer in Clinical Practice

Volumn 8, Issue 1, 2010, Pages

  Møller, Pål ^a   Mæhle, Lovise ^a   Engebretsen, Lars F ^b   Ludvigsen, Trond ^c   Jonsrud, Christoffer ^d   Apold, Jaran ^b   Vabø, Anita ^a   Clark, Neal ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; FEMALE; FOUNDER EFFECT; GENE MUTATION; GENETIC COUNSELING; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PENETRANCE; PROSPECTIVE STUDY;

EID: 79551539311     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-8-2     Document Type: Article

References (21)

1. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995, 56(1):265-71. 1801337, 7825587.
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-30. 10.1086/375033, 1180265, 12677558.
3. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008, 299(2):194-201. 10.1001/jama.2007.55-a, 2714486, 18182601.
4. Dørum A, Heimdal K, Hovig E, Inganäs M, Møller P. Penetrances of BRCA1 1675delA and 1135insA with respect to breast and ovarian cancer. Am J Hum Genet 1999, 65:671-679. 10.1086/302530, 1377973, 10441573.
5. Einbeigi Z, Bergman A, Kindblom LG, Martinsson T, Meis-Kindblom JM, Nordling M, Suurküla M, Wahlström J, Wallgren A, Karlsson P. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur J Cancer 2001, 37(15):1904-9. 10.1016/S0959-8049(01)00223-4, 11576847.
6. King MC, Marks JH, Mandell JB, . New York Breast Cancer Study Group Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302(5645):643-6. 10.1126/science.1088759, 14576434, New York Breast Cancer Study Group.
7. Heimdal K, Mæhle L, Apold J, Pedersen JC, Møller P. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Europ J Cancer 2003, 39:2205-2213.
8. Evans DG, Lennard F, Pointon LJ, Ramus SJ, Gayther SA, Sodha N, Kwan-Lim GE, Leach MO, Warren R, Thompson D, Easton DF, Eeles R, . UK Study of MRI Screening for Breast Cancer in Women at High Risk (MARIBS) Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study. Cancer Epidemiol Biomarkers Prev 2009, 18(7):2123-31. 10.1158/1055-9965.EPI-09-0138, 19567506, UK Study of MRI Screening for Breast Cancer in Women at High Risk (MARIBS).
9. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345(3):159-64. 10.1056/NEJM200107193450301, 11463009.
10. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008, 8:155. 10.1186/1471-2407-8-155, 2447846, 18513387.
11. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008, 82(4):937-48. 10.1016/j.ajhg.2008.02.008, 2427217, 18355772.
12. Møller P, Evans G, Haites N, Vasen H, Reis MM, Anderson E, Apold J, Hodgson S, Eccles D, Olsson H, Stoppa-Lyonnet D, Chang-Claude J, et al. Guidelines for follow-up of women at high risk for inherited breast cancer. Consensus statement from the Biomed2 Demonstration Programme on Inherited Breast Cancer. Dis Markers 1999, 15:207-2011.
13. Evans GR, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous M, Vasen HF, van Asperen C, Moller P. Screening for Familial Ovarian Cancer: Poor survival of BRCA1/2 related cancers. J Med Genet 2008, 46:593-597. 10.1136/jmg.2008.058248, 18413372.
14. Hagen Anne I, Kvistad K, Maehle L, Holmen M, Aase H, Styr B, Vabø A, Apold J, Skaane P, Møller P. Sensitivity of MRI versus mammography to diagnose BRCA-associated breast cancer validated in a national prospective series. The Breast 2007, 16(4):367-74. 10.1016/j.breast.2007.01.006, 17317184.
15. Moller P, Evans DG, Reis MM, Gregory H, Anderson E, Maehle L, Lalloo F, Howell A, Apold J, Clark N, Lucassen A, Steel CM. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer 2007, 121(5):1017-20. 10.1002/ijc.22789, 17471561.
16. Møller P, Hagen AI, Apold J, Maehle L, Clark N, Fiane B, Løvslett K, Hovig E, Vabø A. Genetic epidemiology of BRCA mutation - family history identifies less than 50% of mutation carriers. Eur J Cancer 2007, 43(11):1713-7. 10.1016/j.ejca.2007.04.023, 17574839.
17. Mæhle L, Apold J, Paulsen T, Hagen B, Løvslett K, Fiane B, vGhelue M, Clark N, Møller P. High risk for ovarian cancer in a prospective series is restricted to BRCA mutation carriers. Clin Cancer Res 2008, 14(22):7569-73. 10.1158/1078-0432.CCR-08-0112, 19010876.
18. Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska T, Haus O, Janiszewska H, Niepsuj S, Góźdź S, Zaremba L, Posmyk M, Płuzañska M, Kilar E, Czudowska D, Waśko B, Miturski R, Kowalczyk JR, Urbañski K, Szwiec M, Koc J, Debniak B, Rozmiarek A, Debniak T, Cybulski C, Kowalska E, Tołoczko-Grabarek A, Zajaczek S, Menkiszak J, Medrek K, Masojæ B, Mierzejewski M, Narod SA, Lubiñski J. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004, 110(5):683-6. 10.1002/ijc.20162, 15146557.
19. Bodd TL, Reichelt J, Heimdal K, Møller P. Uptake of BRCA1 genetic testing in adult sisters and daughters of known mutation carriers in Norway. J Genet Counselling 2003, 5:405-417.
20. Evans G, Baildam A, Brain A, Anderson E, Shenton A, Vasen HF, Eccles D, Lucassen AM, Pichert G, Hamed H, Møller P, Mahle L, Morrison PJ, Stoppat-Lyonnet D, Gregory H, Smyth E, Niederacher D, Nestle-Krämling C, Campbell J, Hopwood P, Lalloo F, Howell A. Risk reducing mastectomy: outcomes in 10 European Centres. J Med Genet 2008, 46:254-8. 10.1136/jmg.2008.062232, 18996907.
21. Hill AB. Principles of medical statistics 1971, 327. The Lancet Limited, London.